These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23965490)

  • 1. External Quality Assessment (EQA) program for the preanalytical and analytical immunohistochemical determination of HER2 in breast cancer: an experience on a regional scale.
    Terrenato I; Arena V; Pizzamiglio S; Pennacchia I; Perracchio L; Buglioni S; Ercolani C; Sperati F; Costarelli L; Bonanno E; Baldini D; Candia S; Crescenzi A; Dal Mas A; Di Cristofano C; Gomes V; Grillo LR; Pasquini P; Pericoli MN; Ramieri MT; Di Stefano D; Ruco L; Scarpino S; Vitolo D; d'Amati G; Paradiso A; Verderio P; Mottolese M
    J Exp Clin Cancer Res; 2013 Aug; 32(1):58. PubMed ID: 23965490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China.
    Pu T; Shui R; Shi J; Liang Z; Yang W; Bu H; Li Q; Zhang Z;
    BMC Cancer; 2019 Oct; 19(1):978. PubMed ID: 31640622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment.
    Ekholm M; Grabau D; Bendahl PO; Bergh J; Elmberger G; Olsson H; Russo L; Viale G; Fernö M
    Acta Oncol; 2015 Jul; 54(7):1040-8. PubMed ID: 25959664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens.
    Tsuda H; Kurosumi M; Umemura S; Yamamoto S; Kobayashi T; Osamura RY
    BMC Cancer; 2010 Oct; 10():534. PubMed ID: 20925963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.
    Powell WC; Hicks DG; Prescott N; Tarr SM; Laniauskas S; Williams T; Short S; Pettay J; Nagle RB; Dabbs DJ; Scott KM; Brown RW; Grogan T; Roche PC; Tubbs RR
    Appl Immunohistochem Mol Morphol; 2007 Mar; 15(1):94-102. PubMed ID: 17536315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations.
    Bianchi S; Caini S; Paglierani M; Saieva C; Vezzosi V; Baroni G; Simoni A; Palli D;
    Pathol Oncol Res; 2015 Apr; 21(2):477-85. PubMed ID: 25367072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Internal quality control on HER2 status determination in breast cancers: Experience of a cancer center].
    Ngo C; Laé M; Ratour J; Hamel F; Taris C; Caly M; Le Cunff A; Reyal F; Kirova Y; Pierga JY; Vincent-Salomon A
    Bull Cancer; 2017; 104(7-8):608-617. PubMed ID: 28595742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interobserver reproducibility of immunohistochemical HER-2/neu evaluation in human breast cancer: the real-world experience.
    Int J Biol Markers; 2004; 19(2):147-54. PubMed ID: 15255548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland -on behalf of the UK national coordinating committee for breast pathology.
    Zaakouk M; Quinn C; Provenzano E; Boyd C; Callagy G; Elsheikh S; Flint J; Millican-Slater R; Gunavardhan A; Mir Y; Makhija P; Di Palma S; Pritchard S; Tanchel B; Rakha E; Atallah NM; Lee AHS; Pinder S; Shaaban AM
    Breast; 2023 Aug; 70():82-91. PubMed ID: 37419078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays.
    Laurinaviciene A; Dasevicius D; Ostapenko V; Jarmalaite S; Lazutka J; Laurinavicius A
    Diagn Pathol; 2011 Sep; 6():87. PubMed ID: 21943197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated UK Recommendations for HER2 assessment in breast cancer.
    Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
    J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry.
    Wang J; Yoon E; Krishnamurthy S
    Ann Diagn Pathol; 2024 Jun; 70():152288. PubMed ID: 38452457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis.
    Turashvili G; Leung S; Turbin D; Montgomery K; Gilks B; West R; Carrier M; Huntsman D; Aparicio S
    BMC Cancer; 2009 May; 9():165. PubMed ID: 19476653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interlaboratory concordance in HER2 testing: Results of a Serbian ring-study.
    Ivkovic-Kapic T; Knezevic Usaj S; Moldvaji E; Jovanic I; Milovanovic Z; Milentijevic M; Tatic S; Mitrovic S; Stojiljkovic M; Cvetanovic A
    J BUON; 2019; 24(3):1045-1053. PubMed ID: 31424659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low-Expressing Breast Cancer Cohort.
    Karakas C; Tyburski H; Turner BM; Wang X; Schiffhauer LM; Katerji H; Hicks DG; Zhang H
    Am J Clin Pathol; 2023 May; 159(5):484-491. PubMed ID: 36856777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard.
    Umemura S; Osamura RY; Akiyama F; Honma K; Kurosumi M; Sasano H; Toyoshima S; Tsuda H; Rüschoff J; Sakamoto G
    Am J Clin Pathol; 2008 Dec; 130(6):883-91. PubMed ID: 19019764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 status determination: analyzing the problems to find the solutions.
    Terrenato I; Pennacchia I; Buglioni S; Mottolese M; Arena V
    Medicine (Baltimore); 2015 Apr; 94(15):e645. PubMed ID: 25881836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study.
    Buza N; Euscher ED; Matias-Guiu X; McHenry A; Oliva E; Ordulu Z; Parra-Herran C; Rottmann D; Turner BM; Wong S; Hui P
    Mod Pathol; 2021 Jun; 34(6):1194-1202. PubMed ID: 33536574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis.
    Hameed O; Adams AL; Baker AC; Balmer NE; Bell WC; Burford HN; Chhieng DC; Jhala NC; Klein MJ; Winokur T
    Am J Clin Pathol; 2008 Sep; 130(3):425-7. PubMed ID: 18701416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AutoIHC-Analyzer: computer-assisted microscopy for automated membrane extraction/scoring in HER2 molecular markers.
    Tewary S; Arun I; Ahmed R; Chatterjee S; Mukhopadhyay S
    J Microsc; 2021 Jan; 281(1):87-96. PubMed ID: 32803890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.